https://www.selleckchem.com/pr....oducts/tasquinimod.h
In the subgroup analysis based on the continent, the ROSC rate (OR 0.521; 95% CI 0.432-0.628) and survival-to-discharge rate (OR 0.102; 95% CI 0.066-0.156) were significantly lower in the North American group. SB use was not associated with improvement in ROSC or survival-to-discharge rates in cardiac resuscitation. In addition, mortality was significantly increased in the North American group with SB administration. SB use was not associated with improvement in ROSC or survival-to-discharge rates in cardiac resuscitation. In additi
Мне нравится
Комментарий
Перепост
